Toby Maher on ENV-101 in patients with idiopathic pulmonary fibrosis

Toby Maher joins us to discuss results of a randomised, double-blind, placebo-controlled, proof-of-concept trial of ENV-101, an oral inhibitor of the hedgehog signalling pathway, in patients with idiopathic pulmonary fibrosis. Read the full article: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00239-5/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanres Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/t...